Compare Revvity Inc (RVTY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Revvity Inc trades at $115.87 (market cap $12.91B), while Vanguard Total World Stock Index Fund ETF trades at $161.49. The key difference: Revvity Inc pays a 0.24% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| RVTY | VT | |
|---|---|---|
Market Cap | $12.91B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $117.75 | $161.30 |
52-Week Low | $82.26 | $132.19 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
VT trades at $161.59, up 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF's broad diversification across over 10,000 global stocks provides stability, though RSI levels indicate potential overbought conditions. Recent news highlights institutional activity, including Barry Investment Advisors reducing its stake by 18.7% in Q2 2026 (SEC filing, August 10, 2026).
Outlook remains positive due to global exposure and low expense ratio, but risks include trade war uncertainties and seasonal volatility. Analysts note fair valuation with a mid-to-high teens P/E and 11.4% long-term EPS growth (Seeking Alpha, July 25, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
